ImmunityBio Inc (NASDAQ:IBRX) shares rose 8.6% in premarket trading Wednesday after the company announced the FDA accepted its supplemental Biologics License Application for ANKTIVA in combination ...

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative ...

ImmunityBio (IBRX) stock jumps as the FDA agrees to review the company's bid to expand the label for bladder cancer therapy ...

Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds. These dead cells are ...

IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales ...

ImmunityBio Inc. IBRX presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ...

Photocure ASA reported new real-world data presented at the American Urological Association 2026 congress showing that Blue Light Cystoscopy significantly improves early detection of carcinoma in situ ...

The ongoing LEGEND phase 2 trial is testing a novel, investigational non-viral, intravesical gene therapy (EG-70) in patients with BCG-unresponsive NMIBC to elicit a local innate and adaptive immune ...

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results ...

Why do adolescents and young adults with cancer require special treatment considerations, and how can proton therapy help ...

An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...